Research News & Publications

Novel beta-thalassemia treatment shows promise in preclinical tests

08/21/2019

A fresh take on the common blood disorder, b-thalassemia leads researchers to a novel therapy using rapamycin that is ready for clinical trial.
St. Jude Children’s Research Hospital names Dr. Aseem Ansari chair of Department of Chemical Biology and Therapeutics

08/15/2019

Aseem Ansari, Ph.D., will join St. Jude Children’s Research Hospital as chair of the Department of Chemical Biology and Therapeutics.
Evaluating pediatric cancer through the lens of time

07/29/2019

New study accounts for years of life lost due to cancer. It’s the first time this metric has been used to analyze the childhood cancer burden globally.
To understand a childhood brain tumor, researchers turn to single-cell analysis

07/24/2019

Research at St. Jude Children’s Research Hospital and Massachusetts General Hospital digs into the cells of origin for key medulloblastoma subtypes.
Too little or too much DUX4 is just right

07/11/2019

St. Jude researchers discover protein that may improve treatment for B-ALL in some patients. Learn more about how this gene’s expression impacts development.
Scientists follow the data to a surprise

06/27/2019

Researchers surveyed the accumulation of toxic proteins in Alzheimer’s models, and discovered that a pathway nicknamed LANDO can limit the protein buildup.
Childhood leukemia cannot hide from the immune system

06/26/2019

St. Jude scientists found that despite having few mutations, pediatric acute lymphoblastic leukemia does not escape immune detection.
Leukemia mutations: sometimes less is more

06/26/2019

It’s true that adult tumors often have more mutations. Young ALL patients have fewer mutations, but the T cells identify more than two-thirds of them.
Goldilocks principle helps explain the origins of the most common children’s cancer

06/26/2019

This study provided the first detailed genomic and epigenomic map of the IGH-DUX4 rearrangement and suggested the principle a model for the IGH-DUX4 contribution to B-ALL.
Researchers discover key genetic trigger that compromises cancer immunotherapy

06/17/2019

T cell exhaustion has proven to be an obstacle for immunotherapy, and investigators hope their basic findings will result in techniques to prevent exhaustion.